Septerna, Inc.
$26.86
▲
3.32%
2026-04-21 09:21:02
septerna.com
NGM: SEPN
Explore Septerna, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.17 B
Current Price
$26.86
52W High / Low
$32.63 / $5.73
Stock P/E
—
Book Value
$8.52
Dividend Yield
—
ROCE
-15.87%
ROE
-12.19%
Face Value
—
EPS
$-1.1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
130
Beta
—
Debt / Equity
6.19
Current Ratio
4.73
Quick Ratio
4.73
Forward P/E
-11.87
Price / Sales
22.57
Enterprise Value
$669.42 M
EV / EBITDA
-8.45
EV / Revenue
14.57
Rating
None
Target Price
$44.43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
| 2. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 3. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 4. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 5. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 6. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 7. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 24.12 M | 21.5 M | 0.12 M | 0.22 M | 0.21 M | — |
| Operating Profit | -16.02 M | -9.89 M | -28.98 M | -25.91 M | -24.72 M | — |
| Net Profit | -10.74 M | 8.17 M | -24.84 M | -21.48 M | -20.67 M | — |
| EPS in Rs | -0.24 | 0.18 | -0.55 | -0.48 | -0.46 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 45.95 M | 1.07 M | 0.15 M | 0 M |
| Operating Profit | -80.8 M | -80.82 M | -45.55 M | -27.97 M |
| Net Profit | -48.88 M | -71.8 M | 4.18 M | -27.68 M |
| EPS in Rs | -1.09 | -1.6 | 0.09 | -0.62 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 596.19 M | 456.55 M | 130.87 M | 36.12 M |
| Total Liabilities | 214.26 M | 36.51 M | 169.24 M | 80.32 M |
| Equity | 381.93 M | 420.05 M | -38.37 M | -44.2 M |
| Current Assets | 410.96 M | 356.82 M | 112.68 M | 31.89 M |
| Current Liabilities | 86.93 M | 12.85 M | 6.91 M | 5.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 110.19 M | -67.47 M | -38.72 M | -23.3 M |
| Investing CF | -229.35 M | -160.6 M | 22.12 M | -1.29 M |
| Financing CF | 1.69 M | 377.78 M | 74.52 M | 30.05 M |
| Free CF | 109.67 M | -69.57 M | -41.6 M | -24.59 M |
| Capex | -0.52 M | -2.1 M | -2.88 M | -1.29 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 4174.51% | 611.92% | — | — |
| Earnings Growth % | 31.92% | -1817.66% | 115.1% | — |
| Profit Margin % | -106.37% | -6678.88% | 2768.21% | — |
| Operating Margin % | -175.83% | -7518.42% | -30165.56% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -172.34% | -7388.09% | -29603.97% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.